Show simple item record

dc.contributor.authorColomba, E
dc.contributor.authorLe Teuff, G
dc.contributor.authorEisen, T
dc.contributor.authorStewart, GD
dc.contributor.authorFife, K
dc.contributor.authorLarkin, J
dc.contributor.authorBiondo, A
dc.contributor.authorPickering, L
dc.contributor.authorSrinivasan, A
dc.contributor.authorBoyle, H
dc.contributor.authorDerosa, L
dc.contributor.authorSternberg, CN
dc.contributor.authorRecine, F
dc.contributor.authorRalph, C
dc.contributor.authorSaldana, C
dc.contributor.authorBarthélémy, P
dc.contributor.authorBernhard, JC
dc.contributor.authorGurney, H
dc.contributor.authorVerhoest, G
dc.contributor.authorVauleon, E
dc.contributor.authorBigot, P
dc.contributor.authorBerger, J
dc.contributor.authorPfister, C
dc.contributor.authorGravis, G
dc.contributor.authorRodier, J-M
dc.contributor.authorCuline, S
dc.contributor.authorCaty, A
dc.contributor.authorRolland, F
dc.contributor.authorPriou, F
dc.contributor.authorEscudier, B
dc.contributor.authorAlbiges, L
dc.date.accessioned2020-10-13T14:29:15Z
dc.date.issued2017-07
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2017, 80 pp. 55 - 62
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4143
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2017.03.011
dc.description.abstractBackground Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.Methods We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.Results 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).Conclusion We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
dc.formatPrint-Electronic
dc.format.extent55 - 62
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectCarcinoma, Renal Cell
dc.subjectKidney Neoplasms
dc.subjectAngiogenesis Inhibitors
dc.subjectAntineoplastic Agents
dc.subjectEnzyme Inhibitors
dc.subjectTreatment Failure
dc.subjectSurvival Analysis
dc.subjectRetrospective Studies
dc.subjectTime Factors
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectKaplan-Meier Estimate
dc.subjectTOR Serine-Threonine Kinases
dc.subjectMolecular Targeted Therapy
dc.titleMetastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
dc.typeJournal Article
dcterms.dateAccepted2017-03-13
rioxxterms.versionofrecord10.1016/j.ejca.2017.03.011
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume80
pubs.embargo.termsNot known
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record